{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:39:06Z","timestamp":1793295546191,"version":"4.5.0"},"reference-count":40,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Mounting evidence links systemic innate immunity with cancer immune surveillance. In advanced metastatic castration-resistant prostate cancer (mCRPC), Black patients have been found to have increased inflammatory markers and longer survival after sipuleucel-T (sip-T) therapy, an FDA-approved, autologous cell therapy. We hypothesized these differences may be explained by previously reported ancestral differences in pattern recognition receptor signaling, which broadly governs innate inflammation to control adaptive immune cell activation, chemotaxis, and functionality. We discovered that peripheral blood mononuclear cell IFN-\u03b2 responses to Toll-like receptor 1\/2 (TLR1\/2), a sensor of bacterial and gut microbiome constituents, associated with significantly longer survival after sip-T therapy in two separate cohorts of men with mCRPC (discovery cohort: n = 106, HR = 0.12; P = 0.019; validation cohort: n = 28, HR &amp;lt; 0.01; P = 0.047). Higher IFN-\u03b2 induction after TLR1\/2 stimulation was associated with lower HRs than biomarkers of vaccine potency and other prognostic factors in mCRPC. TLR1\/2-dependent cytokine induction was stronger in Black individuals (1.2-fold higher for IFN-\u03b2; P = 0.04) but was associated with survival independently of race or numbers of vaccine-induced tumor antigen\u2013specific T cells. IFN-\u03b2 responses to TLR1\/2 signaling correlated with increased numbers of IFN-\u03b3 producing T cells after broad, tumor antigen\u2013independent stimulation. Thus, peripheral innate immunity differs by race, may predict survival after sip-T, and associates with peripheral T-cell functionality in men with mCRPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The identification of factors that determine successful cancer immunotherapy, particularly in refractory tumor types like mCRPC, is urgently needed: both to identify patients that may benefit from such therapies and to uncover routes to sensitize patients with cancer to immunotherapy. Our work links functional peripheral immune responses with race and survival after cellular immunotherapy in men with mCRPC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-24-0439","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T11:30:08Z","timestamp":1727263808000},"page":"2724-2733","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Peripheral Blood IFN Responses to Toll-Like Receptor 1\/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T"],"prefix":"10.1158","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3957-1164","authenticated-orcid":false,"given":"Michael C.","family":"Brown","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Duke University School of Medicine, Durham, North Carolina. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8536-633X","authenticated-orcid":false,"given":"Vincent M.","family":"D\u2019Anniballe","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University School of Medicine, Durham, North Carolina. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2240-7229","authenticated-orcid":false,"given":"David","family":"Boczkowski","sequence":"additional","affiliation":[{"name":"Department of Surgery, Duke University School of Medicine, Durham, North Carolina. 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3606-0595","authenticated-orcid":false,"given":"Harini","family":"Kandadi","sequence":"additional","affiliation":[{"name":"Dendreon Pharmaceuticals, LLC, Seattle, Washington. 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8926-136X","authenticated-orcid":false,"given":"Nadeem","family":"Sheikh","sequence":"additional","affiliation":[{"name":"Dendreon Pharmaceuticals, LLC, Seattle, Washington. 4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0250-3504","authenticated-orcid":false,"suffix":"Jr","given":"William","family":"Kornahrens","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Duke University School of Medicine, Durham, North Carolina. 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1381-2713","authenticated-orcid":false,"given":"Elisabeth I.","family":"Heath","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute, Wayne State University, Detroit, Michigan. 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3876-9555","authenticated-orcid":false,"given":"Archana","family":"Thakur","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Virginia School of Medicine, Charlottesville, Virginia. 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6048-1860","authenticated-orcid":false,"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute, Wayne State University, Detroit, Michigan. 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7561-6035","authenticated-orcid":false,"given":"Lawrence","family":"Lum","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Virginia School of Medicine, Charlottesville, Virginia. 6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0075-3745","authenticated-orcid":false,"given":"Frank C.","family":"Cackowski","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute, Wayne State University, Detroit, Michigan. 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1711-4998","authenticated-orcid":false,"given":"Julie","family":"Boerner","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute, Wayne State University, Detroit, Michigan. 5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4602-0667","authenticated-orcid":false,"given":"Michael D.","family":"Gunn","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University School of Medicine, Durham, North Carolina. 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7012-1754","authenticated-orcid":false,"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University School of Medicine, Durham, North Carolina. 2"},{"name":"Department of Surgery, Duke University School of Medicine, Durham, North Carolina. 3"},{"name":"Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, North Carolina. 7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7019-1912","authenticated-orcid":false,"given":"Smita K.","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Duke University School of Medicine, Durham, North Carolina. 1"},{"name":"Department of Surgery, Duke University School of Medicine, Durham, North Carolina. 3"},{"name":"Department of Pathology, Duke University School of Medicine, Durham, North Carolina. 8"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"2025040317300395200_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/PPO.0000000000000048","article-title":"Microbiome, inflammation, and cancer","volume":"20","author":"Francescone","year":"2014","journal-title":"Cancer J"},{"key":"2025040317300395200_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"2025040317300395200_bib3","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.ccell.2021.08.006","article-title":"Microbiome and cancer","volume":"39","author":"Cullin","year":"2021","journal-title":"Cancer Cell"},{"key":"2025040317300395200_bib4","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.tim.2023.05.006","article-title":"Monocyte regulation by gut microbial signals","volume":"31","author":"Kolypetri","year":"2023","journal-title":"Trends Microbiol"},{"key":"2025040317300395200_bib5","doi-asserted-by":"crossref","first-page":"e004688","DOI":"10.1136\/jitc-2022-004688","article-title":"Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy","volume":"10","author":"Hwang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025040317300395200_bib6","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","article-title":"Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors","volume":"12","author":"Valero","year":"2021","journal-title":"Nat Commun"},{"key":"2025040317300395200_bib7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/s41590-022-01262-7","article-title":"Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy","volume":"23","author":"Boukhaled","year":"2022","journal-title":"Nat Immunol"},{"key":"2025040317300395200_bib8","doi-asserted-by":"crossref","first-page":"16072","DOI":"10.1073\/pnas.1918937117","article-title":"Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy","volume":"117","author":"Griffiths","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025040317300395200_bib9","doi-asserted-by":"crossref","first-page":"e005052","DOI":"10.1136\/jitc-2022-005052","article-title":"Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma","volume":"10","author":"Beasley","year":"2022","journal-title":"J ImmunoTherapy Cancer"},{"key":"2025040317300395200_bib10","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41467-022-28407-4","article-title":"The induction of peripheral trained immunity in the pancreas incites anti-tumor activity to control pancreatic cancer progression","volume":"13","author":"Geller","year":"2022","journal-title":"Nat Commun"},{"key":"2025040317300395200_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41590-023-01428-x","article-title":"Influenza-trained mucosal-resident alveolar macrophages confer long-term antitumor immunity in the lungs","volume":"24","author":"Wang","year":"2023","journal-title":"Nat Immunol"},{"key":"2025040317300395200_bib12","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cell.2020.09.058","article-title":"Innate immune training of granulopoiesis promotes anti-tumor activity","volume":"183","author":"Kalafati","year":"2020","journal-title":"Cell"},{"key":"2025040317300395200_bib13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","article-title":"Defining trained immunity and its role in health and disease","volume":"20","author":"Netea","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"2025040317300395200_bib14","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"2025040317300395200_bib15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41391-020-0213-7","article-title":"Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry","volume":"23","author":"Sartor","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2025040317300395200_bib16","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1002\/cncr.32445","article-title":"Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer","volume":"125","author":"Higano","year":"2019","journal-title":"Cancer"},{"key":"2025040317300395200_bib17","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/1078-0432.CCR-20-2925","article-title":"Comparative genomics reveals distinct immune-oncologic pathways in African American men with prostate cancer","volume":"27","author":"Awasthi","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025040317300395200_bib18","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1158\/1078-0432.CCR-18-1060","article-title":"IFNL4-\u0394G allele is associated with an interferon signature in tumors and survival of African-American men with prostate cancer","volume":"24","author":"Tang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025040317300395200_bib19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/s41467-021-21245-w","article-title":"Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes","volume":"12","author":"Weiner","year":"2021","journal-title":"Nat Commun"},{"key":"2025040317300395200_bib20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/jnci\/djab145","article-title":"Analysis of circulating immune biomarkers by race in men with metastatic castration-resistant prostate cancer treated with sipuleucel-T","volume":"114","author":"Hawley","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"2025040317300395200_bib21","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1158\/2767-9764.CRC-24-0112","article-title":"Race-related differences in sipuleucel-T response among men with metastatic castrate-resistant prostate cancer","volume":"4","author":"Heath","year":"2024","journal-title":"Cancer Res Commun"},{"key":"2025040317300395200_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00262-012-1317-2","article-title":"Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer","volume":"62","author":"Sheikh","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"2025040317300395200_bib23","doi-asserted-by":"crossref","first-page":"3619","DOI":"10.1158\/1078-0432.CCR-14-2334","article-title":"Humoral immune response against nontargeted tumor antigens after treatment with sipuleucel-T and its association with improved clinical outcome","volume":"21","author":"GuhaThakurta","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2025040317300395200_bib24","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.1158\/1078-0432.CCR-18-0638","article-title":"Antigen-specific CD8 lytic phenotype induced by sipuleucel-T in hormone-sensitive or castration-resistant prostate cancer and association with overall survival","volume":"24","author":"Antonarakis","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025040317300395200_bib25","doi-asserted-by":"crossref","first-page":"dju268","DOI":"10.1093\/jnci\/dju268","article-title":"Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer","volume":"106","author":"Fong","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2025040317300395200_bib26","volume-title":"Immunobiology","author":"Janeway","year":"2001"},{"key":"2025040317300395200_bib27","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cell.2016.09.024","article-title":"Genetic adaptation and neandertal admixture shaped the immune system of human populations","volume":"167","author":"Quach","year":"2016","journal-title":"Cell"},{"key":"2025040317300395200_bib28","doi-asserted-by":"crossref","first-page":"7520","DOI":"10.4049\/jimmunol.178.12.7520","article-title":"Cutting edge: a common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy","volume":"178","author":"Johnson","year":"2007","journal-title":"J Immunol"},{"key":"2025040317300395200_bib29","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1206095","article-title":"The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota","volume":"332","author":"Round","year":"2011","journal-title":"Science"},{"key":"2025040317300395200_bib30","doi-asserted-by":"crossref","first-page":"230","DOI":"10.4049\/jimmunol.1701216","article-title":"Innate recognition of the microbiota by TLR1 promotes epithelial homeostasis and prevents chronic inflammation","volume":"201","author":"Kamdar","year":"2018","journal-title":"J Immunol"},{"key":"2025040317300395200_bib31","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/s12276-023-01075-0","article-title":"Microbiota-dependent regulation of costimulatory and coinhibitory pathways via innate immune sensors and implications for immunotherapy","volume":"55","author":"Park","year":"2023","journal-title":"Exp Mol Med"},{"key":"2025040317300395200_bib32","doi-asserted-by":"crossref","first-page":"e000277","DOI":"10.1136\/jitc-2019-000277","article-title":"Endogenous TLR2 ligand embedded in the catalytic region of human cysteinyl-tRNA synthetase 1","volume":"8","author":"Cho","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025040317300395200_bib33","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1111\/j.1582-4934.2010.01127.x","article-title":"Endogenous toll-like receptor ligands and their biological significance","volume":"14","author":"Yu","year":"2010","journal-title":"J Cell Mol Med"},{"key":"2025040317300395200_bib34","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1126\/science.aay9189","article-title":"The human tumor microbiome is composed of tumor type-specific intracellular bacteria","volume":"368","author":"Nejman","year":"2020","journal-title":"Science"},{"key":"2025040317300395200_bib35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13073-022-01011-3","article-title":"Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling","volume":"14","author":"Salachan","year":"2022","journal-title":"Genome Med"},{"key":"2025040317300395200_bib36","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/s41467-021-22088-1","article-title":"Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling","volume":"12","author":"Brown","year":"2021","journal-title":"Nat Commun"},{"key":"2025040317300395200_bib37","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.3390\/cancers14174149","article-title":"The effect of age on prostate cancer survival","volume":"14","author":"Clark","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025040317300395200_bib38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/annonc\/mdx742","article-title":"Age at diagnosis and prostate cancer treatment and prognosis: a population-based cohort study","volume":"29","author":"Pettersson","year":"2018","journal-title":"Ann Oncol"},{"key":"2025040317300395200_bib39","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/S0022-5347(01)67332-4","article-title":"Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer","volume":"153","author":"Fowler","year":"1995","journal-title":"J Urol"},{"key":"2025040317300395200_bib40","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2016.09.025","article-title":"Genetic ancestry and natural selection drive population differences in immune responses to pathogens","volume":"167","author":"N\u00e9d\u00e9lec","year":"2016","journal-title":"Cell"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-24-0439\/3500712\/crc-24-0439.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/10\/2724\/3508030\/crc-24-0439.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/4\/10\/2724\/3508030\/crc-24-0439.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T01:52:38Z","timestamp":1743731558000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/4\/10\/2724\/749174\/Peripheral-Blood-IFN-Responses-to-Toll-Like"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,1]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-24-0439","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.28727848","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727836","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727839","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727833","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727854","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727857","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27255828","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27255852","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27255840","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27255861","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727851","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27255849","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27255837","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.28727842","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27255825","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27255858","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27255846","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27255834","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27255855","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27255843","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.27255831","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.7499751","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,1]]}}}